Table 1. Patient information.
| Characteristic | Total patients, n = 41 |
|---|---|
| Histological findings | |
| Steatosis score, n (%) 0/1/2/3 | 0 (0)/24 (58.4)/8 (19.5)/9 (22) |
| Lobular inflammation score, n (%) 0/1/2/3 | 0 (0)/15 (36.6)/20 (48.8)/6 (14.6) |
| Ballooning score, n (%) 0/1/2 | 19 (46.3)/12 (29.3)/10 (24.4) |
| NAS score n (%) 2/3/4/5/6/7/8 | 7 (17.1)/8 (19.5%)/9 (22)/8 (19.5)/6 (14.6)/2 (4.9)/1 (2.4) |
| Fibrosis stage, n (%) 0/1/2/3/4 | 8 (19.5)/10 (24.4)/7 (17.1)/12 (29.3)/4 (9.8) |
| Demographics | |
| Age, median (IQR), years | 55 (43–63) |
| Male, n (%) | 13 (31.7) |
| Diabetes/Impaired Fasting Glycemia, n (%) | 28 (68.3) |
| HTN, n (%) | 19 (46.3) |
| Dyslipidemia, n (%) | 13 (31.7) |
| BMI, median (IQR), kg/m2 | 29.94 (26.20–33.46) |
| Laboratory findings | |
| Hemoglobin, median (IQR), g/dL | 14.0 (13.5–14.8) |
| WBC, median (IQR), × 103/μL | 6.60 (5.20–8.60) |
| PLT, median (IQR), × 103/μL | 206 (169–239) |
| AST, median (IQR), IU/L | 61 (42–79) |
| ALT, median (IQR), IU/L | 80 (50–112) |
| ALP (IU/L), median (IQR), IU/L | 95 (80–113) |
| GGT (IU/L), median (IQR), IU/L | 76 (49–103) |
| Bilirubin, median (IQR), mg/dL | 0.54 (0.43–0.67) |
| Albumin, median (IQR), g/dL | 4.3 (4.1–4.4) |
| PT, median (IQR), INR | 1.01 (0.97–1.05) |
| BUN, median (IQR), mg/dL | 13.6 (11.7–15.1) |
| Creatinine, median (IQR), mg/dL | 0.64 (0.56–0.78) |
| CRP, median (IQR), mg/L | 2.41 (1.10–4.07) |
n, number of patients; IQR, interquartile range; HTN, hypertension; BMI, body mass index; WBC, white blood cell; PLT, platelet; AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase; GGT, gamma glutamyl; PT, prothrombin time; BUN, blood urea nitrogen; CRP, C-reactive protein.